Cargando…

Immunoadsorption as maintenance therapy for refractory neuromyelitis optica spectrum disorder

BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune disease of the central nervous system, affecting mainly optic nerves and spinal cord. NMOSD pathophysiology is associated with anti-aquaporin-4 (AQP4) immunoglobulin G (IgG) autoantibodies. Rapid extracorporeal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heigl, Franz, Hettich, Reinhard, Fassbender, Cordula, Klingel, Reinhard, Mauch, Erich, Durner, Joachim, Kern, Rolf, Kleiter, Ingo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905021/ https://www.ncbi.nlm.nih.gov/pubmed/36762319 http://dx.doi.org/10.1177/17562864221150314

Ejemplares similares

Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy – successful treatment with lipoprotein apheresis
por: Heigl, Franz, et al.
Publicado: (2017)

Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica
por: Hoffmann, Frank, et al.
Publicado: (2018)

Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
por: Trebst, Corinna, et al.
Publicado: (2013)

Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis
por: Koziolek, Michael J, et al.
Publicado: (2012)

Visual Evoked Potentials in Neuromyelitis Optica Spectrum Disorders
por: Hernandez Fustes, Otto Jesus, et al.
Publicado: (2021)

Ovarian Reserve in Women With Neuromyelitis Optica Spectrum Disorder
por: Thöne, Jan, et al.
Publicado: (2018)

Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology
por: Fujihara, Kazuo, et al.
Publicado: (2020)

Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
por: Krumbholz, Markus, et al.
Publicado: (2015)

Demographic and clinical features of neuromyelitis optica: A review
por: Pandit, L, et al.
Publicado: (2015)

Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease
por: Heigl, Franz, et al.
Publicado: (2015)

Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study
por: Klingel, Reinhard, et al.
Publicado: (2015)

Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines
por: Klingel, Reinhard, et al.
Publicado: (2017)

Neuromyelitis Optica
por: Misra, M. C., et al.
Publicado: (1953)

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)

Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study
por: Seyed Ahadi, Maral, et al.
Publicado: (2021)

Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder
por: Holmøy, Trygve, et al.
Publicado: (2020)

Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica
por: Paul, Friedemann, et al.
Publicado: (2007)

The history of neuromyelitis optica
por: Jarius, Sven, et al.
Publicado: (2013)

Neuromyelitis optica and neuroregeneration
Publicado: (2012)

Immunotherapy of Neuromyelitis Optica
por: Bienia, Benjamin, et al.
Publicado: (2013)

Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders
por: Lebrun, Christine, et al.
Publicado: (2018)

Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: Onset Following Acute COVID-19 Infection, a Case Series
por: Avila, Mirla, et al.
Publicado: (2022)

Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico
por: Zarei, Sara, et al.
Publicado: (2018)

The Big Yawning: Pathological Yawning as a Symptom of Neuromyelitis Optica Spectrum Disorders
por: Spahlinger, Veronika, et al.
Publicado: (2019)

New Insights into Neuromyelitis Optica
por: Kim, Woojun, et al.
Publicado: (2011)

Experimental Models of Neuromyelitis Optica
por: Bradl, Monika, et al.
Publicado: (2013)

Molecular Pathogenesis of Neuromyelitis Optica
por: Bukhari, Wajih, et al.
Publicado: (2012)

B lymphocytes in neuromyelitis optica
por: Bennett, Jeffrey L., et al.
Publicado: (2015)

Update on biomarkers in neuromyelitis optica
por: Melamed, Esther, et al.
Publicado: (2015)

Multisystem involvement in neuromyelitis optica
por: Langille, Megan M., et al.
Publicado: (2015)

A Case of Neuromyelitis Optica
por: DE, M. N., et al.
Publicado: (1946)

A Case of Neuromyelitis Optica
por: Shone, S.
Publicado: (1940)

The Gut Microbiome in Neuromyelitis Optica
por: Zamvil, Scott S., et al.
Publicado: (2017)

Treatment strategies for neuromyelitis optica
por: Huang, Tzu-Lun, et al.
Publicado: (2018)

Cognitive Impairment in Neuromyelitis Optica
por: YABALAK, Ahmet, et al.
Publicado: (2020)

Educational Case: Neuromyelitis optica
por: Kitchens, Nathaniel, et al.
Publicado: (2022)

Neuromyelitis Optica Spectrum Disorder
por: Cazzaniga, Juliana, et al.
Publicado: (2023)

A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica
por: Giovannelli, Jonathan, et al.
Publicado: (2021)

Refractory hyponatremia in neuromyelitis optica in a pediatric patient: A case report
por: Lin, Tai-Han, et al.
Publicado: (2021)

Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders
por: Fan, Xueli, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jchuhmkh8p10vf9o6tsgnvfond